[go: up one dir, main page]

AR094146A1 - Unidad solida con alto contenido en fexofenadina y su procedimiento de preparacion - Google Patents

Unidad solida con alto contenido en fexofenadina y su procedimiento de preparacion

Info

Publication number
AR094146A1
AR094146A1 ARP130104869A ARP130104869A AR094146A1 AR 094146 A1 AR094146 A1 AR 094146A1 AR P130104869 A ARP130104869 A AR P130104869A AR P130104869 A ARP130104869 A AR P130104869A AR 094146 A1 AR094146 A1 AR 094146A1
Authority
AR
Argentina
Prior art keywords
fexofenadine
weight
solid unit
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
ARP130104869A
Other languages
English (en)
Inventor
Lanne Jean
Yves - Renouard Marie
Merillon Baptiste
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47902228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR094146(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR094146A1 publication Critical patent/AR094146A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a composiciones farmacéuticas, destinadas a ser utilizadas en forma de unidad sólida tal como un comprimido, para una administración por vía oral, que comprenden un alto contenido en fexofenadina y/o en al menos una de sus sales farmacéuticamente aceptables, así como a los procedimientos de fabricación de unidades sólidas por vía hot melt. Reivindicación 1: Unidad sólida que contiene una dosis de 5 a 500 mg de fexofenadina y/o de al menos una de sus sales farmacéuticamente aceptables, cuya composición es la siguiente: 45 a 92% en peso de fexofenadina y/o de al menos una de sus sales farmacéuticamente aceptables, opcionalmente en asociación con al menos otro principio activo, 4 a 20% en peso de un excipiente termofusible o mezcla de excipientes termofusibles, presentando dicho(s) excipiente(s) fusible(s) una temperatura de fusión o una temperatura de transición vítrea superior o igual a 35ºC e inferior o igual a 115ºC, y 4 a 50% en peso de un excipiente adicional o de una pluralidad de excipientes adicionales, expresándose los porcentajes en peso sobre el peso total de la composición
ARP130104869A 2012-12-21 2013-12-19 Unidad solida con alto contenido en fexofenadina y su procedimiento de preparacion AR094146A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1262647A FR2999937B1 (fr) 2012-12-21 2012-12-21 Unite solide a haute teneur en fexofenadine et son procede de preparation

Publications (1)

Publication Number Publication Date
AR094146A1 true AR094146A1 (es) 2015-07-15

Family

ID=47902228

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104869A AR094146A1 (es) 2012-12-21 2013-12-19 Unidad solida con alto contenido en fexofenadina y su procedimiento de preparacion

Country Status (24)

Country Link
US (1) US9757340B2 (es)
EP (1) EP2934491B1 (es)
JP (1) JP6276287B2 (es)
KR (1) KR20150100725A (es)
CN (1) CN105073101B (es)
AR (1) AR094146A1 (es)
AU (1) AU2013366512B2 (es)
BR (1) BR112015014137B8 (es)
CA (1) CA2895607A1 (es)
CL (1) CL2015001681A1 (es)
EA (1) EA030982B1 (es)
ES (1) ES2625447T3 (es)
FR (1) FR2999937B1 (es)
HU (1) HUE032393T2 (es)
IL (1) IL239267A0 (es)
MX (1) MX360047B (es)
PH (1) PH12015501377A1 (es)
PL (1) PL2934491T3 (es)
SG (1) SG11201504394TA (es)
TN (1) TN2015000267A1 (es)
TW (1) TWI624275B (es)
UY (1) UY35235A (es)
WO (1) WO2014096387A1 (es)
ZA (1) ZA201504079B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124981A1 (en) 2013-02-14 2014-08-21 Sanofi Chewable composition for oral administration and process for preparing thereof
WO2017073738A1 (ja) * 2015-10-29 2017-05-04 日本臓器製薬株式会社 フェキソフェナジンを有効成分とする錠剤
EP4119130A4 (en) * 2020-03-11 2024-01-31 Sawai Pharmaceutical Co., Ltd. GRANULES AND THEIR USE
EP4119129A4 (en) 2020-03-11 2024-01-24 Sawai Pharmaceutical Co., Ltd. GRANULES AND THEIR USE
WO2023145871A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用組成物の製造方法及び製剤の製造方法
WO2023145869A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用組成物の製造方法及び製剤の製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1044319C (zh) * 1984-08-30 1999-07-28 默里尔多药物公司 热熔融抗组胺组合物的制备方法
DK164642C (da) * 1984-08-30 1992-12-14 Merrell Dow Pharma Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler
DK0812195T3 (da) 1995-02-28 2003-03-03 Aventis Pharma Inc Farmaceutisk sammensætning til piperidinoalkanolforbindelser
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
EP1454635B1 (en) * 2003-03-07 2007-12-19 Ind-Swift Limited Tasteless, directly compressible, fast-dissolving complexes and pharmaceutical formulations thereof
FR2959130A1 (fr) * 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
WO2014124981A1 (en) 2013-02-14 2014-08-21 Sanofi Chewable composition for oral administration and process for preparing thereof

Also Published As

Publication number Publication date
MX2015008068A (es) 2016-04-25
AU2013366512B2 (en) 2017-11-09
CN105073101A (zh) 2015-11-18
EA030982B1 (ru) 2018-10-31
SG11201504394TA (en) 2015-07-30
US20150313885A1 (en) 2015-11-05
IL239267A0 (en) 2015-07-30
AU2013366512A1 (en) 2015-07-09
MX360047B (es) 2018-10-19
CL2015001681A1 (es) 2015-08-21
BR112015014137A2 (pt) 2017-07-11
CN105073101B (zh) 2018-10-09
UY35235A (es) 2014-07-31
EP2934491A1 (en) 2015-10-28
BR112015014137B1 (pt) 2022-12-13
FR2999937A1 (fr) 2014-06-27
PH12015501377A1 (en) 2015-09-02
EA201591150A1 (ru) 2015-11-30
WO2014096387A1 (en) 2014-06-26
FR2999937B1 (fr) 2015-01-09
BR112015014137B8 (pt) 2023-01-24
TW201431569A (zh) 2014-08-16
PL2934491T3 (pl) 2017-09-29
JP6276287B2 (ja) 2018-02-07
HK1211234A1 (en) 2016-05-20
ZA201504079B (en) 2016-04-28
US9757340B2 (en) 2017-09-12
KR20150100725A (ko) 2015-09-02
TWI624275B (zh) 2018-05-21
ES2625447T3 (es) 2017-07-19
CA2895607A1 (en) 2014-06-26
HUE032393T2 (en) 2017-09-28
JP2016511223A (ja) 2016-04-14
TN2015000267A1 (en) 2016-10-03
EP2934491B1 (en) 2017-02-22

Similar Documents

Publication Publication Date Title
AR094146A1 (es) Unidad solida con alto contenido en fexofenadina y su procedimiento de preparacion
AR117001A2 (es) Formulación de premezcla de dexmedetomidina
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
CL2007002485A1 (es) Proceso para preparar una forma de dosificacion farmaceutica oral solida de leberacion extendida que comprende un agente aactivo y oxido de polietileno de peso molecular de al menos 1.000.000, que incluye un paso de curado sometiendola a la temperatura de reblandecimiento o fusion (al menos parcial) del oxido de polietileno.
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
BR112016000909A8 (pt) derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
MX354102B (es) Derivados de bencimidazol-prolina.
ECSP11011555A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
ECSP12011958A (es) Composiciones farmacéuticas que comprenden ligandos de receptores sigma
HRP20161231T1 (hr) Farmaceutske formulacije koje sadrže derivate 1-(beta-d-glukopiranozil)-2-tienilmetilbenzena kao sglt inhibitore
NI201200189A (es) "composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona"
BR112015011430A2 (pt) composição para liberação imediata e prolongada
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
CR20140540A (es) Nueva forma de dosificación y formulación de abediterol
BR112012032463A2 (pt) composição farmacêutica para administração oral.
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
CO6351721A2 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
PE20091560A1 (es) Comprimido de desintegracion oral
PE20142460A1 (es) Composiciones farmaceuticas orales estables de liberacion inmediata que contienen prasugrel
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.

Legal Events

Date Code Title Description
FB Suspension of granting procedure